Barclays analyst Peter Lawson maintained a Hold rating on Blueprint Medicines (BPMC – Research Report) today and set a price target of $105.00.

Fintel reports that on February 10, 2025, Barclays downgraded their outlook for Illumina (NasdaqGS:ILMN) from Equal-Weight to ...

Operator Hello and welcome to McDonald's fourth quarter 2024 investor conference call. At the request of McDonald's ...

If you’re currently not happy with your interest rate it could be worth refinancing and getting a better deal. Understanding how Australia's demographics will shape future housing preferences is an ...